Comparison of toxicity associated with nonmedical use of benzodiazepines with buprenorphine or methadone

Drug and Alcohol Dependence

Volumn 138, Issue 1, 2014, Pages 118-123

  Lee, Samantha C ^a   Klein Schwartz, Wendy ^b   Doyon, Suzanne ^b,c   Welsh, Christopher ^d  

^a Hennepin Regional Poison Center   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Abuse; Benzodiazepines; Buprenorphine; Methadone; Nonmedical use

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE; METHADONE; NALOXONE; BENZODIAZEPINE DERIVATIVE; NARCOTIC ANALGESIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; AGITATION; ARTICLE; BRADYCARDIA; CARDIOTOXICITY; CLINICAL FEATURE; COMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIAPHORESIS; DRUG ABUSE; DRUG EFFECT; DRUG EXPOSURE; DRUG INTOXICATION; DRUG MISUSE; ENDOTRACHEAL INTUBATION; FEMALE; HEALTH CARE UTILIZATION; HEART ARREST; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPOTENSION; INCIDENCE; INTENSIVE CARE UNIT; IRRITABILITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; RESPIRATION DEPRESSION; RESPIRATORY ARREST; RETROSPECTIVE STUDY; TACHYCARDIA; VOMITING; ADDICTION; ADOLESCENT; COMPARATIVE STUDY; DRUG INTERACTION; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; BENZODIAZEPINES; BUPRENORPHINE; DRUG INTERACTIONS; FEMALE; HOSPITALIZATION; HUMANS; MALE; METHADONE; MIDDLE AGED; RETROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897525367     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.02.014     Document Type: Article

References (63)

1. Aeschbach Jachmann C., Jaqsch R., Winklbaur B., Matzenauer C., Fischer G. Office-based treatment in opioid dependence: a critical survey of prescription practices for opioid maintenance medications and concomitant benzodiazepines in Vienna, Austria. Eur. Addict. Res. 2008, 14:206-212.
2. Alhaddad H., Cisternino S., Saubamea B., Schlatter J., Chiadmi F., Risède P., Smirnova M., Cochois-Guegan V., Tournier N., Baud F.J., Megarbane B. Gender and strain contributions to the variability of buprenorphine-related respiratory toxicity in mice. Toxicology 2013, 305:99-108.
3. Alhaddad H., Cisternino S., Declèves X., Tournier N., Schlatter J., Chiadmi F., Risede P., Smirnova M., Besengez C., Scherrmann J.M., Baud F.J., Megarbane B. Respiratory toxicity of buprenorphine results from blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice. Crit. Care Med. 2012, 40:3215-3223.
4. Baud F.J. Mechanisms of opioid-induced overdose: experimental approach to clinical concerns. Ann. Pharm. Fr. 2009, 67:353-359.
5. Bernard J.P., Havnes I., Slordal L., Wall H., Morland J., Khiabani H. Methadone-related deaths in Norway. Forensic Sci. Int. 2013, 224:111-116.
6. Brenet O., Harry P., LeBouil A., Cailleux A., Geffroy S., Jouan P.L., Alquier P. Intoxication mortelle liée à l'association buprénorphine-benzodiazépines. Réan Urg. 1998, 7:673.
7. Centers for Disease Control and Prevention (CDC), 2010. Emergency department visits involving nonmedical use of selected prescription drugs - United States, 2004-2008. MMWR 59, 705-709.
8. Chevillard L., Mégarbane B., Risède P., Baud F.J. Characteristics and comparative severity of respiratory response to toxic doses of fentanyl, methadone, morphine and buprenorphine in rats. Toxicol. Lett. 2009, 191:327-340.
9. Cowan A., Doxey J.C., Harry E.J.R. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br. J. Pharmacol. 1997, 60:547-554.
10. Dahan A., Yassen A., Romberg R., Sarton E., Teppema L., Olofsen E., Danhof M. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br. J. Anaesthiol. 2006, 96:627-632.
11. Debruyne D., Quentin T., Poisnel G., Lelong-Boulard V., Barre L., Coquerel A. Acute and chronic administration of clorazepate modifies the cell surface regulation of μ opioid receptors induced by buprenorphine in specific regions of the rat brain. Brain Res. 2005, 1052:222-231.
12. Drake C.T., Milner T.A. Mu-opioid receptors are in somatodendritic and axonal compartments of GABAergic neurons in rat hippocampal formation. Brain Res. 1999, 849:203-215.
13. Drummer O.H., Syrjanen M.J., Cordner S.M. Deaths involving the benzodiazepine flunitrazepam. Am. J. Forensic Med. Pathol. 1993, 14:238-243.
14. Faroqui M.H., Cole M., Curran J. Buprenorphine, benzodiazepines and respiratory depression. Anaesthesia 1983, 38:1002-1003.
15. Forrest A.L. Buprenorphine and lorazepam. Anaesthesia 1983, 38:598.
16. Green D.W. Buprenorphine, benzodiazepines and respiratory depression. Anaesthesia 1984, 39:287-288.
17. Gopal S., Tzeng T.B., Cowan A. Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine. Eur. J. Pharm. Sci. 2002, 15:287-289.
18. Gueye P.N., Borron S.W., Risede P., Monier C., Buneaux F., Debray M., Baud F.J. Buprenorphine and midazolam act in combination to depress respiration in rats. Toxicol. Sci. 2002, 65:107-114.
19. Gueye P.N., Borron S.W., Risède P., Monier C., Buneaux F., Debray M., Baud F.J. Lack of effect of single high doses of buprenorphine on arterial blood gases in the rat. Toxicol. Sci. 2001, 62:148-154.
20. Hammersley R., Cassidy M.T., Oliver J. Drugs associated with drug-related deaths in Edinburgh and Glasgow, November 1990 to October 1992. Addiction 1995, 90:959-965.
21. Iguchi M.Y., Handelsman L., Bickel W.K., Griffiths R.R. Benzodiazepine and sedative use/abuse by methadone maintenance clients. Drug Alcohol Depend. 1993, 32:257-266.
22. Jones A.W., Holmgren A., Ahlner J. Blood methadone concentrations in living and deceased persons: variations over time, subject demographics and relevance of coingested drugs. J. Anal. Toxicol. 2012, 36:12-18.
23. A- receptors are co-expressed by neurons in rat brain. Neuroreport 2000, 11:2625-2628.
24. Kay B. Buprenorphine, benzodiazepines and respiratory depression. Anaesthesia 1984, 39:491-492.
25. Kintz P., Villain M., Tracqui A., Cirimele V., Ludes B. Buprenorphine in drug-facilitated sexual abuse: a fatal case involving a 14-year-old boy. J. Anal. Toxicol. 2003, 27:527-529.
26. Kintz P. A new series of 13 buprenorphine related deaths. Clin. Biochem. 2002, 35:513-516.
27. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci. Int. 2001, 121:65-69.
28. Lalley P.M. Mu-opioid receptor agonist effects on medullary respiratory neurons in the cat: evidence for involvement in certain types of ventilatory disturbances. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285:R1287-R1304.
29. Lavie E., Fatséas M., Denis C., Auriacombe M. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence. Drug Alcohol Depend. 2009, 99:338-344.
30. Lee S.C., Klein-Schwartz W., Welsh C., Doyon S. Medical outcomes associated with nonmedical use of methadone and buprenorphine. J. Emerg. Med. 2013, 45:199-205.
31. Lintzeris N., Nielson S. Benzodiazepines, methadone and buprenorphine: Interactions and clinical management. Am. J. Addict. 2009, 19:59-72.
32. Megarbane B., Buisine A., Jacobs F., Resiere D., Chevillard L., Vicaut E., Baud F.J. Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment. J. Subst. Abuse Treat. 2010, 38:403-407.
33. Mégarbane B., Hreiche R., Pirnay S., Marie N., Baud F.J. Does high-dose buprenorphine cause respiratory depression? possible mechanism and therapeutic consequences. Toxicol. Rev. 2006, 225:79-85.
34. Megarbane B., Marie N., Pirnay S. Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol. Appl. Pharmacol. 2006, 212:256-267.
35. Megarbane B., Pirnay S., Borron S.W., Trout H., Monier C., Risède P., Boschi G., Baud F.J. Flunitrazepam does not alter cerebral distribution of buprenorphine in the rat. Toxicol. Lett. 2005, 157:211-219.
36. Mikolaenko I., Robinson C.A., Davis G.G. A review of methadone deaths in Jefferson County, Alabama. Am. J. Forensic Med. Pathol. 2002, 23:299-304.
37. Nielsen S., Dietze P., Lee N., Dunlop A., Taylor D. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction 2007, 102:12-616.
38. Ng W.L., Mythily S., Song G., Chan Y.H., Winslow M. Concomitant use of midazolam and buprenorphine and its implications among drug users in Singapore. Ann. Acad. Med. Singapore 2007, 36:774-777.
39. Ohtani M., Kotaki H., Sawada Y., Iga T. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J. Pharmacol. Exp. Ther. 1995, 272:505-510.
40. Ohtani M., Kotaki H., Uchino K., Sawada Y., Iga T. Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats. Drug Metab. Dispos. 1994, 22:2-7.
41. Pattinson K.T. Opioids and the control of respiration. Br. J. Anaesth. 2008, 100:747-758.
42. Pedapati E.V., Bateman S.T. Toddlers requiring pediatric intensive care unit admission following at-home exposures to buprenorphine/naloxone. Pediatr. Crit. Care Med. 2011, 12:e102-e109.
43. Pirnay S., Megarbane B., Declèves X., Risède P., Borron S.W., Bouchonnet S., Perrin B., Debray M., Milan N., Duarte T., Ricordel I., Baud F.J. Buprenorphine alters desmethylflunitrazepam disposition and flunitrazepam toxicity in rats. Toxicol. Sci. 2008, 106:64-73.
44. Pirnay S., Borron S.W., Giudicelli C.P., Tourneau J., Baud F.J., Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 2004, 99:978-988.
45. Poisnel G., Dhilly M., Le Boisselier R., Barre L., Debruyne D. Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced μ-opioid receptor regulation. J. Pharmacol. Sci. 2009, 110:36-46.
46. Reynaud M., Tracqui A., Petit G., Potard D., Courty P. Six deaths linked to misuse of buprenorphine-benzodiazepine combinations. Am. J. Psychiatry 1998, 155:447.
47. Reynaud M., Petit G., Potard D., Courty P. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998, 93:1385-1392.
48. Schroeder C.A., Smith L.J. Respiratory rates and arterial blood-gas tensions in healthy rabbits given buprenorphine, butorphanol, midazolam, or their combinations. J. Am. Assoc. Lab. Anim. Sci. 2011, 5:205-211.
49. Schuman-Oliver Z., Hoeppner B.B., Weiss R.D., Borodovsky J., Shaffer H.J., Albanese M.J. Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes. Drug Alcohol Depend. 2013, 132:580-586.
50. Sekar M., Mimpriss T.J. Buprenorphine, benzodiazepines and prolonged respiratory depression. Anaesthesia 1987, 42:567-568.
51. Substance Abuse and Mental Health Services Administration (SAMHSA) The DAWN Report: Methadone-Related Emergency Department Visits Involving Nonmedical Use 2012, Center for Behavioral Statistics and Quality, Rockville, MD.
52. Substance Abuse Mental Health Services Administration (SAMHSA) The DAWN Report: Outcomes of Drug-Related Emergency Department Visits Associated with Polydrug Use 2012, Center for Behavioral Statistics and Quality, Rockville, MD.
53. Substance Abuse and Mental Health Services Administration, (SAMHSA) The DAWN Report: Highlights of the 2010 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits 2012, Center for Behavioral Health Statistics and Quality, Rockville, MD.
54. Substance Abuse and Mental Health Services Administration (SAMHSA) The TEDS Report: Admissions Reporting Benzodiazepine and Narcotic Pain Reliever Abuse at Treatment Entry 2012, Center for Behavioral Health Statistics and Quality, Rockville, MD.
55. Substance Abuse and Mental Health Services Administration (SAMHSA) The DAWN Report: Emergency Department Visits Involving Buprenorphine 2013, Center for Behavioral Health Statistics and Quality, Rockville, MD.
56. Thorn S.E., Rawal N., Wennhager M. Prolonged respiratory depression caused by sublingual buprenorphine. Lancet 1998, 1:179-180.
57. Tournier N., Chevillard L., Megarbane B., Pirnay S., Scherrmann J.M., Declèves X. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int. J. Neuropsychopharmacol. 2010, 13:905-915.
58. Tracqui A., Kintz P., Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J. Anal. Toxicol. 1998, 22:430-434.
59. Tracqui A., Tournoud C., Flesch F., Kopferschmitt J., Kintz P., Deveaux M., Ghysel M.H., Marquet P., Pepin G., Petit G., Jaeger A., Ludes B. Intoxication aiguës par traitement substitutive à base de buprénorphine haut dosage. 29 observations cliniques-20 cas mortels. Press. Méd. 1998, 27:557-561.
60. Warner M., Chen L.H., Makuc D.M. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006 2009, National Center for Health Statistics, Hyattsville, MD, NCHS Data Brief, no. 22.
61. Wish E.D., Artigiani E., Billing A., Hauser W., Hemberg J., Shiplet M., DuPont R.L. The emerging buprenorphine epidemic in the United States. J. Addict. Dis. 2012, 31:3-7.
62. Yassen A., Olofsen E., Romberg R. Sarton, E., Teppema, L., Danhof, M., Dahan, A.,. Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clin. Pharmacol. Ther. 2007, 81:50-58.
63. Yassen A., Kan J., Olofsen E., Suidgeest E., Dahan A., Danhof M. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of buprenorphine and fentanyl in rats. J. Pharmacol. Exp. Ther. 2005, 81:50-58.